Bone morphogenetic protein signaling in prostate cancer cell lines

Journal of Cellular Biochemistry

Volumn 91, Issue 1, 2004, Pages 151-160

  Brubaker, K D ^a   Corey, E ^a   Brown, L G ^a   Vessella, R L ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Bone morphogenetic receptors (BMPRs); Osteoprotegerin (OPG); p21CIP1 WAF1; p27KIP1; Retinoblastoma (Rb); SMAD 1

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; CYCLIN DEPENDENT KINASE INHIBITOR 1; SMAD1 PROTEIN; BMP2 PROTEIN, HUMAN; BONE MORPHOGENETIC PROTEIN; CDKN1A PROTEIN, HUMAN; CELL RECEPTOR; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; DNA BINDING PROTEIN; GLYCOPROTEIN; OSTEOPROTEGERIN; RETINOBLASTOMA PROTEIN; SMAD PROTEIN; SMAD1 PROTEIN, HUMAN; TNFRSF11B PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR RECEPTOR;

BONE METASTASIS; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL STRAIN LNCAP; FLOW CYTOMETRY; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; ARTICLE; BONE TUMOR; CELL CULTURE; CELL DIVISION; DRUG EFFECT; MALE; METABOLISM; METASTASIS; PHOSPHORYLATION; PHYSIOLOGY; PROSTATE TUMOR; SIGNAL TRANSDUCTION; UPREGULATION;

BONE MORPHOGENETIC PROTEINS; BONE NEOPLASMS; CELL DIVISION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA-BINDING PROTEINS; FLOW CYTOMETRY; G1 PHASE; GLYCOPROTEINS; HUMANS; MALE; OSTEOPROTEGERIN; PHOSPHORYLATION; PROSTATIC NEOPLASMS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; RETINOBLASTOMA PROTEIN; SIGNAL TRANSDUCTION; SMAD PROTEINS; SMAD1 PROTEIN; TRANS-ACTIVATORS; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 3242808359     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.10679     Document Type: Review

References (65)

1. Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D, Galibert L. 1997. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390:175-179.
2. Autzen P, Robson CN, Bjartell A, Malcolm AJ, Johnson MI, Neal DE, Hamdy FC. 1998. Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies. Br J Cancer 78:1219-1223.
3. Bae SC, Lee KS, Zhang YW, Ito Y. 2001. Intimate relationship between TGF-beta/BMP signaling and runt domain transcription factor, PEBP2/CBF. J Bone Joint Surg Am 83:S48-S55.
4. Bragg AD, Moses HL, Serra R. 2001. Signaling to the epithelium is not sufficient to mediate all of the effects of transforming growth factor beta and bone morphogenetic protein 4 on murine embryonic lung development. Mech Dev 109:13-26.
5. Brown JM, Vessella RL, Kostenuik PJ, Dunstan CR, Lange PH, Corey E. 2001a. Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. Clin Cancer Res 7:2977-2983.
6. Brown JM, Corey E, Lee ZD, True LD, Yun TJ, Tondravi M, Vessella RL. 2001b. Osteoprotegerin and rank ligand expression in prostate cancer. Urology 57:611-616.
7. Brubaker KD, Thomas R, Vessella RL. 2001. Bone morphogenetic protein receptors (BMPRs) IA, IB, and II mRNA and protein expression in prostate cancer progression. AACR Proc 42:297.
8. Brubaker KD, Vessella RL, Brown LG, Corey E. 2003. Prostate cancer expression of runt-domain transcription factor Runx2, a key regulator of osteoblast differentiation and function. Prostate 56:13-22.
9. Buchkovich K, Duffy LA, Harlow E. 1989. The retinoblastoma protein is phosphorylated during specific phases of the cell cycle. Cell 58:1097-1105.
10. Corey E, Quinn JE, Bladou F, Brown LG, Roudier MP, Brown JM, Buhler KR, Vessella RL. 2002. Establishment and characterization of osseous prostate cancer models: Intra-tibial injection of human prostate cancer cells. Prostate 52:20-33.
11. Douglas RS, Pletcher CH, Nowell PC, Moore JS. 1998. Novel approach for simultaneous evaluation of cell phenotype, apoptosis, and cell cycle using multiparameter flow cytometry. Cytometry 32:57-65.
12. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G. 1997. Osf2/Cbfa1: A transcriptional activator of osteoblast differentiation. Cell 89:747-754.
13. Dunnett CW, Tamhane AC. 1991. Step-down multiple tests for comparing treatments with a control in unbalanced one-way layouts. Stat Med 10:939-947.
14. Ebara S, Nakayama K. 2002. Mechanism for the action of bone morphogenetic proteins and regulation of their activity. Spine 27:S10-S15.
15. Franzen A, Heldin NE. 2001. BMP-7-induced cell cycle arrest of anaplastic thyroid carcinoma cells via p21(CIP1) and p27(KIP1). Biochem Biophys Res Commun 285:773-781.
16. Ghosh-Choudhury N, Ghosh-Choudhury G, Celeste A, Ghosh PM, Moyer M, Abboud SL, Kreisberg J. 2000a. Bone morphogenetic protein-2 induces cyclin kinase inhibitor p21 and hypophosphorylation of retinoblastoma protein in estradiol-treated MCF-7 human breast cancer cells. Biochim Biophys Acta 1497:186-196.
17. Ghosh-Choudhury N, Woodruff K, Qi W, Celeste A, Abboud SL, Ghosh CG. 2000b. Bone morphogenetic protein-2 blocks MDA MB 231 human breast cancer cell proliferation by inhibiting cyclin-dependent kinase-mediated retinoblastoma protein phosphorylation. Biochem Biophys Res Commun 272:705-711.
18. Graham A, Francis-West P, Brickell P, Lumsden A. 1994. The signalling molecule BMP4 mediates apoptosis in the rhombencephalic neural crest. Nature 372:684-686.
19. Hanai J, Chen LF, Kanno T, Ohtani-Fujita N, Kim WY, Guo WH, Imamura T, Ishidou Y, Fukuchi M, Shi MJ, Stavnezer J, Kawabata M, Miyazono K, Ito Y. 1999. Interaction and functional cooperation of PEBP2/CBF with Smads. Synergistic induction of the immunoglobulin germline Calpha promoter. J Biol Chem 274:31577-31582.
20. Harris SE, Harris MA, Mahy P, Wozney J, Feng JQ, Mundy GR. 1994. Expression of bone morphogenetic protein messenger RNAs by normal rat and human prostate and prostate cancer cells. Prostate 24:204-211.
21. Hjertner O, Hjorth-Hansen H, Borset M, Seidel C, Waage A, Sundan A. 2001. Bone morphogenetic protein-4 inhibits proliferation and induces apoptosis of multiple myeloma cells. Blood 97:516-522.
22. Hofbauer LC, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S. 1998. Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. Biochem Biophys Res Commun 250:776-781.
23. Hogan BL. 1996. Bone morphogenetic proteins: Multifunctional regulators of vertebrate development. Genes Dev 10:1580-1594.
24. Huang W, Rudkin GH, Carlsen B, Ishida K, Ghasri P, Anvar B, Yamaguchi DT, Miller TA. 2002. Overexpression of BMP-2 modulates morphology, growth, and gene expression in osteoblastic cells. Exp Cell Res 274:226-234.
25. Ide H, Katoh M, Sasaki H, Yoshida T, Aoki K, Nawa Y, Osada Y, Sugimura T, Terada M. 1997a. Cloning of human bone morphogenetic protein type IB receptor (BMPR-IB) and its expression in prostate cancer in comparison with other BMPRs. Oncogene 14:1377-1382.
26. Ide H, Yoshida T, Matsumoto N, Aoki K, Osada Y, Sugimura T, Terada M. 1997b. Growth regulation of human prostate cancer cells by bone morphogenetic protein-2. Cancer Res 57:5022-5027.
27. Ishisaki A, Yamato K, Hashimoto S, Nakao A, Tamaki K, Nonaka K, ten Dijke P, Sugino H, Nishihara T. 1999. Differential inhibition of Smad6 and Smad7 on bone morphogenetic protein- and activin-mediated growth arrest and apoptosis in B cells. J Biol Chem 274:13637-13642.
28. Iwamura M, Abrahamsson PA, Foss KA, Wu G, Cockett AT, Deftos LJ. 1994. Parathyroid hormone-related protein: A potential autocrine growth regulator in human prostate cancer cell lines. Urology 43:675-679.
29. Javed A, Barnes GL, Jasanya BO, Stein JL, Gerstenfeld L, Lian JB, Stein GS. 2001. Runt homology domain transcription factors (Runx, Cbfa, and AML) mediate repression of the bone sialoprotein promoter: Evidence for promoter context-dependent activity of Cbfa proteins. Mol Cell Biol 21:2891-2905.
30. Jernvall J, Aberg T, Kettunen P, Keranen S, Thesleff I. 1998. The life history of an embryonic signaling center: BMP-4 induces p21 and is associated with apoptosis in the mouse tooth enamel knot. Development 125:161-169.
31. Jones CM, Lyons KM, Hogan BL. 1991. Involvement of bone morphogenetic protein-4 (BMP-4) and Vgr-1 in morphogenesis and neurogenesis in the mouse. Development 111:531-542.
32. Kawamura C, Kizaki M, Yamato K, Uchida H, Fukuchi Y, Hattori Y, Koseki T, Nishihara T, Ikeda Y. 2000. Bone morphogenetic protein-2 induces apoptosis in human myeloma cells with modulation of STAT3. Blood 96: 2005-2011.
33. Kawamura C, Kizaki M, Ikeda Y. 2002. Bone morphogenetic protein (BMP)-2 induces apoptosis in human myeloma cells. Leuk Lymphoma 43:635-639.
34. Kern B, Shen J, Starbuck M, Karsenty G. 2001. Cbfa1 contributes to the osteoblast-specific expression of type I collagen genes. J Biol Chem 276:7101-7107.
35. Kim IY, Lee DH, Ahn HJ, Tokunaga H, Song W, Devereaux LM, Jin D, Sampath TK, Morton RA. 2000. Expression of bone morphogenetic protein receptors type-IA, -IB, and -II correlates with tumor grade in human prostate cancer tissues. Cancer Res 60:2840-2844.
36. Koenig BB, Cook JS, Wolsing DH, Ting J, Tiesman JP, Correa PE, Olson CA, Pecquet AL, Ventura F, Grant RA. 1994. Characterization and cloning of a receptor for BMP-2 and BMP-4 from NIH 3T3 cells. Mol Cell Biol 14:5961-5974.
37. Kretzschmar M, Liu F, Hata A, Doody J, Massague J. 1997. The TGF-beta family mediator Smad1 is phosphorylated directly and activated functionally by the BMP receptor kinase. Genes Dev 11:984-995.
38. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ. 1998. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176.
39. Lamm ML, Podlasek CA, Barnett DH, Lee J, Clemens JQ, Hebner CM, Bushman W. 2001. Mesenchymal factor bone morphogenetic protein 4 restricts ductal budding and branching morphogenesis in the developing prostate. Dev Biol 232:301-314.
40. Lee KS, Kim HJ, Li QL, Chi XZ, Ueta C, Komori T, Wozney JM, Kim EG, Choi JY, Ryoo HM, Bae SC. 2000. Runx2 is a common target of transforming growth factor beta1 and bone morphogenetic protein 2, and cooperation between Runx2 and Smad5 induces osteoblast-specific gene expression in the pluripotent mesenchymal precursor cell line C2C12. Mol Cell Biol 20:8783-8792.
41. Li CY, Suardet L, Little JB. 1995. Potential role of WAF1/Cip1/p21 as a mediator of TGF-beta cytoinhibitory effect. J Biol Chem 270:4971-4974.
42. Li W, Cogswell CA, LoTurco JJ. 1998. Neuronal differentiation of precursors in the neocortical ventricular zone is triggered by BMP. J Neurosci 18:8853-8862.
43. Lind M, Eriksen EF, Bunger C. 1996. Bone morphogenetic protein-2 but not bone morphogenetic protein-4 and -6 stimulates chemotactic migration of human osteoblasts, human marrow osteoblasts, and U2-OS cells. Bone 18: 53-57.
44. Liu F, Ventura F, Doody J, Massague J. 1995. Human type II receptor for bone morphogenic proteins (BMPs): Extension of the two-kinase receptor model to the BMPs. Mol Cell Biol 15:3479-3486.
45. Lyons KM, Pelton RW, Hogan BL. 1989. Patterns of expression of murine Vgr-1 and BMP-2a RNA suggest that transforming growth factor-beta-like genes coordinately regulate aspects of embryonic development. Genes Dev 3:1657-1668.
46. Masuda H, Fukabori Y, Nakano K, Takezawa Y, Suzuki T, Yamanaka H. 2003. Increased expression of bone morphogenetic protein-7 in bone metastatic prostate cancer. Prostate 54:268-274.
47. Mihara K, Cao XR, Yen A, Chandler S, Driscoll B, Murphree AL, T'Ang A, Fung YK. 1989. Cell cycle-dependent regulation of phosphorylation of the human retinoblastoma gene product. Science 246:1300-1303.
48. Nemeth JA, Yousif R, Herzog M, Che M, Upadhyay J, Shekarriz B, Bhagat S, Mullins C, Fridman R, Cher ML. 2002. Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. J Natl Cancer Inst 94:17-25.
49. Nishimura R, Kato Y, Chen D, Harris SE, Mundy GR, Yoneda T. 1998. Smad5 and DPC4 are key molecules in mediating BMP-2-induced osteoblastic differentiation of the pluripotent mesenchymal precursor cell line C2C12. J Biol Chem 273:1872-1879.
50. Pouliot F, Labrie C. 2002. Role of Smad1 and Smad4 proteins in the induction of p21WAF1, Cip1 during bone morphogenetic protein-induced growth arrest in human breast cancer cells. J Endocrinol 172:187-198.
51. Reddi AH. 1998. Role of morphogenetic proteins in skeletal tissue engineering and regeneration. Nat Biotechnol 16: 247-252.
52. Sato M, Morii E, Komori T, Kawahata H, Sugimoto M, Terai K, Shimizu H, Yasui T, Ogihara H, Yasui N, Ochi T, Kitamura Y, Ito Y, Nomura S. 1998. Transcriptional regulation of osteopontin gene in vivo by PEBP2alphaA/CBFA1 and ETS1 in the skeletal tissues. Oncogene 17: 1517-1525.
53. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Boyle WJ. 1997. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89:309-319.
54. Soda H, Raymond E, Sharma S, Lawrence R, Cerna C, Gomez L, Timony GA, Von Hoff DD, Izbicka E. 1998. Antiproliferative effects of recombinant human bone morphogenetic protein-2 on human tumor colony-forming units. Anticancer Drugs 9:327-331.
55. ten Dijke P, Yamashita H, Ichijo H, Franzen P, Laiho M, Miyazono K, Heldin CH. 1994. Characterization of type I receptors for transforming growth factor-beta and activin. Science 264:101-104.
56. Thirunavukkarasu K, Halladay DL, Miles RR, Yang X, Galvin RJ, Chandrasekhar S, Martin TJ, Onyia JE. 2000. The osteoblast-specific transcription factor Cbfa1 contributes to the expression of osteoprotegerin, a potent inhibitor of osteoclast differentiation and function. J Biol Chem 275:25163-25172.
57. Thomas BG, Hamdy FC. 2000. Bone morphogenetic protein-6: Potential mediator of osteoblastic metastases in prostate cancer. Prostate Cancer Prostatic Dis 3:283-285.
58. Thomas R, Anderson WA, Raman V, Reddi AH. 1998. Androgen-dependent gene expression of bone morphogenetic protein 7 in mouse prostate. Prostate 37:236-245.
59. Thomas R, Roudier MP, Brubaker KD, Vessella RL. 2000. Immunolocalization and messenger RNA expression of bone morphogenetic protein-4 (BMP-4) in human prostate cancer progression. J Bone Miner Res 15:8567.
60. Wong GA, Tang V, El-Sabeawy F, Weiss RH. 2003. BMP-2 inhibits proliferation of human aortic smooth muscle cells via p21Cip1/Waf1. Am J Physiol Endocrinol Metab 284:E972-E979.
61. Yamashita H, ten Dijke P, Huylebroeck D, Sampath TK, Andries M, Smith JC, Heldin CH, Miyazono K. 1995. Osteogenic protein-1 binds to activin type II receptors and induces certain activin-like effects. J Cell Biol 130: 217-226.
62. Yeung F, Law WK, Yeh CH, Westendorf JJ, Zhang Y, Wang R, Kao C, Chung LW. 2002. Regulation of human osteocalcin promoter, in hormone-independent human prostate cancer cells. J Biol Chem 277:2468-2476.
63. Yoshida E, Verrusio EN, Mihara H, Oh D, Kwaan HC. 1994. Enhancement of the expression of urokinase-type plasminogen activator from PC-3 human prostate cancer cells by thrombin. Cancer Res 54:3300-3304.
64. Zhang J, Dai J, Qi Y, Lin DL, Smith P, Strayhorn C, Mizokami A, Fu Z, Westman J, Keller ET. 2001. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 107:1235-1244.
65. Zhao GQ, Hogan BL. 1997. Evidence that Mothers-against-dpp-related 1 (Madr1) plays a role in the initiation and maintenance of spermatogenesis in the mouse. Mech Dev 61:63-73.